Arkolith/Insider Trading/AVTX/Form 4

Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed May 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$449K
Net Open-Market Flow
-$449K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 7, 2026Option exercise(M)19K$9.88$184K19K
May 7, 2026Sell(S)19K$24.12$449K423

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 7, 2026Option exercise(M)19K—$0168K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000012) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML